China Biotech Weekly

Briefings

Weekly intelligence on China biotech deals, CDE filings, and BIOSECURE compliance.

16 issues published · Every Thursday since December 2025

Showing 3 briefings tagged “BGI”

·5 min read

China Biotech Weekly #13: The BIOSECURE Countdown — 9 Months Until the BCC List Reshapes China Pharma Partnerships

The OMB has 9 months to publish the BCC list. We break down the three designation categories, track which companies face real exposure, and analyze what AstraZeneca's $18.5B CSPC deal structure tells us about pricing China risk in 2026.

BIOSECUREBCC ListAstraZenecaWuXiBGI
·4 min read

China Biotech Weekly #2: 15 Law Firms Published BIOSECURE Advisories — Here's What They Agree On (and Where They Diverge)

Baker McKenzie, Ropes & Gray, Arnold & Porter, Latham & Watkins, K&L Gates, and 10 more Am Law 100 firms have published BIOSECURE client advisories. We synthesize the consensus, flag where firms disagree on scope and timeline, and extract the compliance checklist every GC needs.

BIOSECUREBCC ListWuXiBGI1260H
·4 min read

Special Issue: BIOSECURE Act Signed Into Law — What BD Teams Need to Know Now

President Trump signed the BIOSECURE Act on December 18, 2025 as part of the FY2026 NDAA. We break down the three BCC designation categories, the implementation timeline, and what this means for your Chinese CDMO contracts — starting today.

BIOSECUREBCC ListWuXiBGICDMO

Get new briefings delivered

Every Thursday. Free. Unsubscribe anytime.